Dr. Riess Discusses PD-L1 Expression in Thymic Malignancies

Jonathan Riess, MD, MS
Published: Thursday, Aug 07, 2014

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray.

As PD-1 and PD-L1 antibodies have demonstrated benefit in other tumor types, Riess says, researchers are curious to analyze these agents for the treatment of thymic malignancies. This analysis was conducted to evaluate thymoma expression of PD-L1, which is a biomarker for response to PD-1 and PD-L1 antibodies.

Results showed that all thymic tumors expressed PD-L1 to some degree, lending support for a clinical trial looking at PD-1 and PD-L1 antibodies in this space.

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray.

As PD-1 and PD-L1 antibodies have demonstrated benefit in other tumor types, Riess says, researchers are curious to analyze these agents for the treatment of thymic malignancies. This analysis was conducted to evaluate thymoma expression of PD-L1, which is a biomarker for response to PD-1 and PD-L1 antibodies.

Results showed that all thymic tumors expressed PD-L1 to some degree, lending support for a clinical trial looking at PD-1 and PD-L1 antibodies in this space.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x